NCT03512119View on ClinicalTrials.gov

Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor

CompletedOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

February 11, 2016

Primary Completion Date

April 10, 2019

Study Completion Date

April 10, 2019

Conditions
Cystic Fibrosis Homozygous for Phe 508 Del CFTRGlucose Intolerance or Newly Diagnosis Diabetes
Interventions
DRUG

Lumacaftor-Ivacaftor treatment

Lumacaftor-Ivacaftor treatment during one year

Trial Locations (13)

13385

Hôpital NORD - Assistance Publique Hôpitaux de Marseille, Marseille

29684

"Clinique Mucoviscidose Presqu'île de Perharidy", Roscoff

34295

Hôpital Arnaud de Villeneuve, Montpellier

37044

Hôpital Bretonneau - CHRU de Tours, Tours

Hôpital de Clocheville - CHRU de Tours, Tours

49033

Centre Hospitalier Universitaire d'Angers, Angers

51092

American Memorial Hospital, Reims

67000

Hôpitaux Universitaires de Strasbourg, Strasbourg

69000

Centre Hospitalier Lyon Sud, Lyon

75019

Hôpital Robert Debré, Paris

76031

Hôpital Charles Nicolle, Rouen

83406

Hôpital Renée Sabran, Giens

92151

Hôpital FOCH, Suresnes

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER

NCT03512119 - Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor | Biotech Hunter | Biotech Hunter